1018782-82-5

Basic information

• Product Name: 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinic acid
• Synonyms: 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinic acid
• CAS NO: 1018782-82-5
• Molecular Formula: C₁₄H₉ClF₃NO₃
• Molecular Weight: 331.6743696
• Mol File: 1018782-82-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinic acid(1018782-82-5)
• EPA Substance Registry System: 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinic acid(1018782-82-5)

Safety Data

• Hazardous Substances Data: 1018782-82-5(Hazardous Substances Data)

Upstream product

• 41668-13-7 5-bromo-6-hydroxy-3-pyridinecarboxylic acid 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 
• 29241-62-1 5-bromo-6-chloronicotinic acid 
• 1012792-55-0 6-chloro-5-(4-chlorophenyl)-3-pyridinecarboxylic acid methyl ester 
• 1012792-56-1 6-chloro-5-(4-chlorophenyl)-3-pyridinecarboxylic acid 
• 75-89-8 2,2,2-trifluoroethanol 

Downstream Products

• 1427064-11-6 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-N'-(2,2,2-trifluoroethyl)-3-pyridinecarboxylic acid hydrazide 

Relevant articles and documents

6-alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds

We identified 6-alkoxy-5-aryl-3-pyridinecarboxamides as potent CB1 receptor antagonists with high selectivity over CB2 receptors. The series was optimized to reduce lipophilicity compared to rimonabant to achieve peripherally active molecules with minimal central effects. Several compounds that showed high plasma exposures in rats were evaluated in vivo to probe the contribution of central vs peripheral CB1 agonism to metabolic improvement. Both rimonabant and 14g, a potent brain penetrant CB1 receptor antagonist, significantly reduced the rate of body weight gain. However, 14h, a molecule with markedly reduced brain exposure, had no significant effect on body weight. PK studies confirmed similarly high exposure of both 14h and 14g in the periphery but 10-fold lower exposure in the brain for 14h. On the basis of these data, which are consistent with reported effects in tissue-specific CB1 receptor KO mice, we conclude that the metabolic benefits of CB1 receptor antagonists are primarily centrally mediated as originally believed.

3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents

The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R1 to R8 and R17 are as defined in the description.